We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Novel Biosensor Detects Neurogenerative Disease Proteins

By LabMedica International staff writers
Posted on 17 Jul 2023
Print article
Image: A single sensor combines multiple advanced technologies to diagnose neurodegenerative diseases (Photo courtesy of EPFL)
Image: A single sensor combines multiple advanced technologies to diagnose neurodegenerative diseases (Photo courtesy of EPFL)

The struggle to diagnose neurodegenerative diseases (NDDs), including Alzheimer's and Parkinson's, has primarily been due to the absence of reliable diagnostic tools for the early detection and tracking of disease progression. One main characteristic of neurodegeneration is protein misfolding, recognized as a significant event in the advancement of the disease. The theory is that in the initial stages, normal proteins misfold into oligomers and, in later stages, into fibrils. These misshaped protein aggregates circulate in the brain and body fluids, as well as accumulate as deposits in the brains of those who died from NDDs. However, the development of tools to identify these disease markers or biomarkers has remained unresolved until now due to various barriers, including the limitations of current technology to accurately distinguish and quantify different protein aggregates.

Researchers at EPFL (Lausanne, Switzerland) have now made a significant breakthrough in NDD diagnosis by combining multiple advanced technologies into a single system. This innovative system dubbed the ImmunoSEIRA sensor, employs biosensing technology to detect and identify misfolded protein biomarkers associated with NDDs. In addition, the system leverages the power of artificial intelligence (AI), utilizing neural networks to quantify disease stages and progression. This groundbreaking advancement offers hope for not only early NDD detection and monitoring but also for evaluating treatment options at different disease progression stages.

The researchers created this sophisticated NDD biomarker sensor by combining various scientific fields: protein biochemistry, optofluidics, nanotechnology, and AI. The ImmunoSEIRA sensor uses a technique called surface-enhanced infrared absorption (SEIRA) spectroscopy, allowing scientists to identify and analyze the structure of specific disease-linked molecules or biomarkers tied to NDDs. The sensor features a unique immunoassay to identify and capture these biomarkers with utmost precision. The ImmunoSEIRA sensor utilizes gold nanorod arrays with antibodies for precise protein detection and facilitates real-time specific capture and structural analysis of target biomarkers from minute samples. AI-driven neural networks are employed to identify the presence of specific misfolded protein forms - the oligomeric and fibrillary aggregates, providing an unprecedented level of detection precision as the diseases progress.

The EPFL researchers went on to demonstrate that the ImmunoSEIRA sensor can be applied in real clinical settings, i.e., in biofluids. They successfully identified the unique signature of abnormal fibrils, a key NDD indicator, even in complex fluids such as human cerebrospinal fluid (CSF). This study's results mark a significant leap in the domains of biosensing, infrared spectroscopy, nanophotonics, and NDD biomarkers. The introduction of the AI-assisted ImmunoSEIRA sensor is a positive development for early NDD detection, disease monitoring, and drug efficacy evaluation, fulfilling the urgent need for prompt intervention and treatment of NDDs.

“Since the disease process is tightly associated with changes in protein structure, we believe that structural biomarkers, especially when integrated with other biochemical and neurodegeneration biomarkers, could pave the way for more precise diagnosis and monitoring of disease progression,” said Professor Hilal Lashuel.

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.